Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Therapeutic Advances in Endocrinology and Metabolism is Scopus-indexed (Q1, CiteScore 8.8), WoS SCIE, DOAJ. Published by Sage Periodicals Press.
Checked against the index lists dated .
ISSN 2042-0188Verify ISSN ↗2042-0196Verify ISSN ↗
Publisher: Sage Periodicals Press
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Endocrinology, Diabetes and Metabolism | 37 / 250 | 85th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2010–present, best quartile Q1, CiteScore 8.8.
Therapeutic Advances in Endocrinology and Metabolism is Q1 in Endocrinology, Diabetes and Metabolism (rank 37 of 250), by CiteScore 2025.
Therapeutic Advances in Endocrinology and Metabolism is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 8.8, which places it in quartile Q1 at the 85th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.642, quartile Q1, with an H-index of 54.
The publisher lists an article processing charge of about US$2,650 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Therapeutic Advances in Endocrinology and Metabolism is published by Sage Periodicals Press. Its print ISSN is 2042-0188 and its online ISSN is 2042-0196.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Therapeutic Advances in Endocrinology and Metabolism has an h-index of 62 and a 2-year mean of 5.46 citations per paper (OpenAlex). Its Scopus CiteScore is 8.8, quartile Q1. On 2-year citations it ranks #29 of 246 Scopus journals in Endocrinology, Diabetes and Metabolism.
Therapeutic Advances in Endocrinology and Metabolism published 61 papers in 2025; its busiest recent year was 2020 with 73. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2025–2026), authors are most often from China (35.6%), Taiwan (8.2%) and Türkiye (6.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (3.1 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.